AAP
KRYS icon

Arax Advisory Partners’s Krystal Biotech KRYS Stock Holding History

Arax Advisory Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.6K Buy
268
+264
+6,600% +$78.9K ﹤0.01% 2733
2026
Q1 		$1.03K Sell
4
-28
-88% -$7.45K ﹤0.01% 3292
2025
Q4 		$7.89K Sell
32
-224
-88% -$47.1K ﹤0.01% 2602
2025
Q3 		$45.2K Buy
256
+250
+4,167% +$37.4K ﹤0.01% 1874
2025
Q2 		$825 Buy
+6
New +$881 ﹤0.01% 2843
2024
Q4 		– Sell
-6
Closed -$1.09K – 2592
2024
Q3 		$1.09K Buy
+6
New +$1.16K ﹤0.01% 2221

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arax Advisory Partners's KRYS Position: Q2 2026 in Review

Arax Advisory Partners increased its Krystal Biotech (KRYS) stake by 6,600% in Q2 2026, buying an estimated $78.9K and bringing the position to 268 shares worth $99.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2733.

Arax Advisory Partners first reported a position in KRYS in Q3 2024 and has held it in 6 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Arax Advisory Partners held 268 shares of Krystal Biotech worth $99.6K as of Q2 2026.
  • Arax Advisory Partners bought 264 Krystal Biotech shares in Q2 2026, an estimated $78.9K.
  • Krystal Biotech made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2733 holding.
  • Arax Advisory Partners first reported a position in Krystal Biotech in Q3 2024 and has held it in 6 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.